Genocea Congratulates Jessica Baker Flechtner, Ph.D. for Recognition on 2016’s 40 Women To Watch Over 40 List
August 09 2016 - 7:30AM
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical
company developing T cell-directed vaccines and immunotherapies, is
delighted to congratulate Jessica Baker Flechtner, Ph.D., chief
scientific officer, who was acknowledged as an honoree on this
year’s 40 Women to Watch Over 40 list. The list, founded in 2013,
celebrates the achievements of women over 40 who are pushing
boundaries in their respective industries.
The 40 Over 40 list highlights an inspiring lineup of women who
are reinventing, disrupting and making an impact in their fields.
In her role as chief scientific officer, Dr. Flechtner leads a team
of scientists and researchers focused on innovation in T cell
target discovery and vaccine development for infectious diseases
and cancers. Dr. Flechtner has been instrumental in expanding the
company’s focus into oncology, establishing important
collaborations with leading academic centers to advance the
understanding of T cell immune responses to cancers and inform
Genocea’s cancer vaccine development strategy.
“This is a well-deserved honor and distinction, and I am
delighted to have had the privilege of working closely with Jessica
over the past several years. Her many successes are an inspiration
to those around her,” said Chip Clark, president and chief
executive officer of Genocea. “In addition to being an accomplished
scientist, strategist and exemplary leader at Genocea, Jessica
serves as a mentor and positive role model for young women
interested in pursuing STEM careers, helping to build the next
generation of biotech leaders.”
Winners were selected based on a rigorous application and
judging process that evaluated three areas: impact, role model and,
reinvention and momentum. To view the complete list of 2016
winners, click here: http://fortyover40.com/honorees/.
About Genocea Biosciences, Inc. Genocea is
harnessing the power of T cell immunity to develop life-changing
vaccines and immunotherapies. T cells are increasingly recognized
as a critical element of protective immune responses to a wide
range of diseases, but traditional discovery methods have proven
unable to identify the targets of such protective immunity. Using
ATLAS, its proprietary technology platform, Genocea identifies
these targets to potentially enable the rapid development of
medicines to address critical patient needs. Genocea's pipeline of
novel clinical stage T cell-enabled product candidates includes
GEN-003 for genital herpes, GEN-004 for the prevention of infection
by all serotypes of pneumococcus (development suspended), and
earlier-stage programs in chlamydia, genital herpes prophylaxis,
malaria and cancer immunotherapy. For more information, please
visit the company's website at www.genocea.com.
For media:
Liz Bryan
Spectrum Science Communications, Inc.
O: 202-955-6222
lbryan@spectrumscience.com
For investors:
Jonathan Poole
Genocea Biosciences, Inc.
O: 617-876-8191
jonathan.poole@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024